Unauthorized HIV Trial Leader Fined

A Spanish researcher faces a penalty after conducting a study for which he never obtained proper approvals or insurance.

By | February 3, 2014

HIV-infected H9 T-cellWIKIMEDIA, NATIONAL INSTITUTES OF HEALTHSpanish HIV/AIDS researcher Vicente Soriano, of Hospital Carlos III in Madrid, is facing a steep fine after violating regulations by conducting a clinical trial involving a new HIV drug without getting the appropriate approvals from Spain’s Agency for Medicines and Health Products. A court of appeals levied the €210,000 ($283,689) fine against Soriano last month (January 14), but overturned a €6,000 ($8,105) fine issued to the researcher for obstructing the initial 2010 investigation into his apparent misdeeds.

Soriano was also charged with failing to obtain proper insurance for the trial and for informing trial participants that he had secured the hospital’s ethical clearance when he had in fact not done so. Soriano is appealing the fines.

The Phase 4 clinical trial started in 2009, when Soriano registered it on The researchers’ aim was to determine if HIV patients with undetectable levels of the virus in their blood could swap out protease inhibitors with a new integrase inhibitor called raltegravir to improve their outcomes and suffer fewer side effects. More than 300 subjects enrolled in the trial, and Soriano and several coauthors published a 2010 HIV Clinical Trials paper reporting that raltegravir sustained viral suppression in most of the subjects who were followed for 24 weeks.

In 2011, a Madrid court issued Soriano €216,000 ($291,714) in fines after an anonymous tipster raised questions about the research. Soriano’s main defense through a lengthy appeals process has been that the study was not a clinical trial, but rather an observational and retrospective study, and therefore was not subject to the approvals of regular clinical trials. Ruth Macklin, a bioethicist at Albert Einstein College of Medicine in New York City, told ScienceInsider she disagreed. "This study was without doubt a clinical trial," that needed proper ethical approval,” she said.

Soriano is maintaining his innocence. He told ScienceInsider in an e-mail that he and his colleagues are victims of “harassment” that seeks to edge his lab out of Hospital Carlos III, which is in the process of merging with another large hospital in Madrid.


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Inside a Lab Mouse’s High-Fat Diet
  2. Battling the Bulge
    Bio Business Battling the Bulge

    Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

  3. How Gastric Bypass Can Kill Sugar Cravings
  4. Birth of the Skin Microbiome
    Daily News Birth of the Skin Microbiome

    The immune system tolerates the colonization of commensal bacteria on the skin with the aid of regulatory T cells during the first few weeks of life, a mouse study shows.

Life Technologies